Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

NCT02384382 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT02384382
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02384382 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY OF 18F-SODIUM FLUORIDE PET/CT BONE IMAGING IN ENZALUTAMIDE-TREATED CHEMOTHERAPY-NAÏVE PATIENTS WITH BONE-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2015
Completion date
May 3, 2019
Enrollment
23 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostate cancer, prostate carcinoma metastatic to the bone